BioCentury | Nov 16, 2015
Clinical News

Phrixus preclinical data

...heart function. Data were published in PLoS ONE. P-188 NF is a non-ionic block copolymer. Phrixus Pharmaceuticals Inc....
BioCentury | Jan 12, 2015
Clinical News

Carmeseal-MD regulatory update

...back to Phrixus. The subcutaneous non-ionic block copolymer is in preclinical testing to treat DMD. Phrixus Pharmaceuticals Inc....
BioCentury | Jul 30, 2012
Clinical News

Phrixus preclinical data

...by hydrophilic ethylene oxide polymers is also in preclinical testing for acute decompensated heart failure. Phrixus Pharmaceuticals Inc....
BioCentury | Jun 25, 2012
Emerging Company Profile

LoneStar Heart: Straight to the heart

...At least one other company is developing a polymer-based product in the heart failure setting. Phrixus Pharmaceuticals Inc....
...Failure Society of America , St. Paul, Minn. LoneStar Heart Inc. , Laguna Hills, Calif. Phrixus Pharmaceuticals Inc....
BioCentury | May 31, 2010
Company News

Senesco management update

...Cancer, Autoimmune, Agbio/Environmental Hired: Leslie Browne as president and CEO, formerly president and CEO of Phrixus Pharmaceuticals Inc....
BioCentury | Apr 8, 2010
Distillery Therapeutics

Indication: Various

...in additional animal models of cardiac injury. Carmeseal poloxamer 188, a nonionic block copolymer from Phrixus Pharmaceuticals Inc....
...to treat heart failure. SciBX 3(14); doi:10.1038/scibx.2010.446 Published online April 8, 2010 Patent application filed; Phrixus...
BioCentury | Jun 29, 2009
Emerging Company Profile

Phrixus: Healing Broken Hearts

...for a range of indications, but the compound never made it past Phase III trials. Phrixus Pharmaceuticals Inc....
...Pharmaceuticals Inc. ) discontinued development in 2006. According to Leslie Browne, president and CEO of Phrixus...
...also has shown P188 provides a benefit in skeletal muscle in a model of DMD. Phrixus...
BioCentury | Jun 29, 2009
Emerging Company Profile

Corporate Profile

Phrixus Pharmaceuticals Inc. Ann Arbor, Mich. Technology: Carmeseal poloxamer 188 Disease focus: Heart failure Clinical status: Phase I Founded: 2006 by Thomas Collet, Bruce Markham and Lorraine Reeve University collaborators: University of Michigan , University of...
Items per page:
1 - 8 of 8
BioCentury | Nov 16, 2015
Clinical News

Phrixus preclinical data

...heart function. Data were published in PLoS ONE. P-188 NF is a non-ionic block copolymer. Phrixus Pharmaceuticals Inc....
BioCentury | Jan 12, 2015
Clinical News

Carmeseal-MD regulatory update

...back to Phrixus. The subcutaneous non-ionic block copolymer is in preclinical testing to treat DMD. Phrixus Pharmaceuticals Inc....
BioCentury | Jul 30, 2012
Clinical News

Phrixus preclinical data

...by hydrophilic ethylene oxide polymers is also in preclinical testing for acute decompensated heart failure. Phrixus Pharmaceuticals Inc....
BioCentury | Jun 25, 2012
Emerging Company Profile

LoneStar Heart: Straight to the heart

...At least one other company is developing a polymer-based product in the heart failure setting. Phrixus Pharmaceuticals Inc....
...Failure Society of America , St. Paul, Minn. LoneStar Heart Inc. , Laguna Hills, Calif. Phrixus Pharmaceuticals Inc....
BioCentury | May 31, 2010
Company News

Senesco management update

...Cancer, Autoimmune, Agbio/Environmental Hired: Leslie Browne as president and CEO, formerly president and CEO of Phrixus Pharmaceuticals Inc....
BioCentury | Apr 8, 2010
Distillery Therapeutics

Indication: Various

...in additional animal models of cardiac injury. Carmeseal poloxamer 188, a nonionic block copolymer from Phrixus Pharmaceuticals Inc....
...to treat heart failure. SciBX 3(14); doi:10.1038/scibx.2010.446 Published online April 8, 2010 Patent application filed; Phrixus...
BioCentury | Jun 29, 2009
Emerging Company Profile

Phrixus: Healing Broken Hearts

...for a range of indications, but the compound never made it past Phase III trials. Phrixus Pharmaceuticals Inc....
...Pharmaceuticals Inc. ) discontinued development in 2006. According to Leslie Browne, president and CEO of Phrixus...
...also has shown P188 provides a benefit in skeletal muscle in a model of DMD. Phrixus...
BioCentury | Jun 29, 2009
Emerging Company Profile

Corporate Profile

Phrixus Pharmaceuticals Inc. Ann Arbor, Mich. Technology: Carmeseal poloxamer 188 Disease focus: Heart failure Clinical status: Phase I Founded: 2006 by Thomas Collet, Bruce Markham and Lorraine Reeve University collaborators: University of Michigan , University of...
Items per page:
1 - 8 of 8